Cometriq（cabozantinib）

[Generic name] Cabozantinib Cometriq
[English name] Cometriq (cabozantinib capsules)
[Chinese name] Cabozantinib mixed capsules
[Manufacturer] Exelixis, Inc

Introduction to cabozantinib drugs
Recently, the European Commission approved Exelixis’ cabozantinib Cometriq (cabozantinib) for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid cancer (MTC). Cabozantinib Cometriq is a selective broad-spectrum tyrosine kinase inhibitor that inhibits VEGF receptor 2 and c-Met receptor tyrosine kinase and has been approved for marketing in the United States. Swedish Orphan Biovitrum AB has the right to sell this product for MTC indications in the European Union, Switzerland, Norway, Russia, Germany, Turkey and other EU countries. This product (MTC indication) has obtained orphan drug status in the European Union.

Cabozantinib Indications and Uses
Cabozantinib COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).

Cabozantinib Dosage and Administration
Recommended dose: 140 mg orally once daily.
Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking cabozantinib COMETRIQ.

Cabozantinib Dosage Forms and Strengths
20 mg and 80 mg capsules.

Contraindications to Cabozantinib
None.

Cabozantinib Warnings and Precautions
Thrombotic Events: Discontinue cabozantinib COMETRIQ for myocardial infarction, cerebral infarction, or other serious arterial thromboembolic events.
Wound Complications: Withhold cabozantinib COMETRIQ for dehiscence or complications requiring medical intervention.
Hypertension: Monitor blood pressure regularly. Discontinue cabozantinib COMETRIQ for hypertensive crisis.
Osteonecrosis of the Jaw: Discontinue COMETRIQ.
Palmar-plantar erythrodysesthesia syndrome (PPES): Interrupt cabozantinib COMETRIQ and reduce dose.
Proteinuria: Monitor urine for protein. Discontinue for nephrotic syndrome.
Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue COMETRIQ.
Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of the potential risk to a fetus.

Cabozantinib Adverse Reactions
The most commonly reported adverse drug reactions (≥25%) were diarrhea, stomatitis, palmar-plantar erythrodysesthesia syndrome (PPES), weight decreased, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation. The most common laboratory abnormalities (≥25%) were increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia.

Cabozantinib Drug Interactions
Cabozantinib is a CYP3A4 substrate. Coadministration of strong CYP3A4 inhibitors may increase cabozantinib exposure. Chronic coadministration of strong CYP3A4 inducers may decrease cabozantinib exposure.